Singapore/Taiwan consecutively invited MEDIPOST to its stem cell forums2015/11/19STEM CELL THERAPEUTIC
‘PNEUMOSTEM’ selected as the ‘Newly developed and promising medical technology’ by National evidence based healthcare collaborating agency2015/11/02STEM CELL THERAPEUTIC
Selected as a conducting company of ‘global high-tech biomedicine industry’2015/10/26STEM CELL THERAPEUTIC
MEDIPOST announced extension plans in US ’2015 Stem Cell Meeting on the Mesa’2015/10/07STEM CELL THERAPEUTIC
US ‘Stem cells regenerative medicine congress’ invites MEDIPOST for the first time as a Korean company2015/09/02STEM CELL THERAPEUTIC
MEDIPOST, achieves ‘150 patent applications and 50 patent registrations’2015/08/27STEM CELL THERAPEUTIC
Core dementia treatment technology patented at 6 European countries, concurrently2015/07/30STEM CELL THERAPEUTIC
‘CARTISTEM’ shows superb results from 3 year long term tracking clinical trials2015/07/23STEM CELL THERAPEUTIC
Lung disease medicine, ‘PNEUMOSTEM’ was designated as ‘Orphan Drug’ in Europe2015/07/06STEM CELL THERAPEUTIC
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022/05/31
